Recently, Advera Health released a comparative safety report of the HER2+ Antagonists. In this drug review, we analyzed FDA Adverse Event Reporting System (FAERS) and clinical trial data to better understand how the drugs in this class stacked up.
This week we launched Evidex Alerts, a new feature that provides our clients with real-time updates on the latest impactful drug safety news. This is a project that our development and analyst teams have worked on diligently for the last three months, and I am excited to announce that it became a reality this week.
Last December, Stat News wrote a scathing report on the chronic under reporting of clinical trial results. We followed that up in July with our own blog post, highlighting specific under reporting rates we’ve found in just a handful of indications.
This week marks the sixth anniversary of the date that Bob Kyle, Henry Duong, and I incorporated Advera Health Analytics. We started this journey with a mission to improve patient outcomes by making drug safety data more accessible and actionable. We spent the early years developing our technologies, building our data delivery platform, and subjecting our early methodologies to peer review. Two years ago we began to commercialize our enterprise data product and since then we’ve grown exponentially.
We were blown away this week by Stat News’ investigation into the blatant underreporting of clinical trials data to the federally mandated ClinicalTrials.gov website. If you haven’t already read this masterful piece of journalism, please do so. No, really. Go ahead and read it. I’ll wait.
Before I get a lot of nasty emails, let me start by saying that although the reader could infer that I am, I ensure you that I AM NOT comparing pharma sales reps to used car salesmen. What I am doing is comparing the pharmaceutical industry, specifically drug safety, to the used car industry before the widespread proliferation of the World Wide Web.